Gynecology/Obstetrics CME

Credits: 1.00 CME
Medical Learning Institute, Inc.
Realizing the Potential of CDK 4/6 Inhibitor Therapy in Breast Cancer: An Examination of the Evidence That Is Informing Real-World Practice
Adam Brufsky, MD, PhD
September 30, 2020
Credits: 1.00 CME / MOC
Medical Learning Institute, Inc.
Making the Most of the New Era of Immuno-Oncology in TNBC: Essential Guidance for Surgeons on How to Maximize the Potential of Immunotherapies and Combinations in Advanced and Early-Stage Breast Cancer
George Plitas, MD
September 21, 2020
Credits: 1.25 CME / MOC / CNE
Medical Learning Institute, Inc.
The Era of Immuno-Oncology in TNBC: Navigating Evidence in Early-Stage and Advanced Disease, Practicalities of Integration, and Implications for Breast Surgeons
George Plitas, MD
August 28, 2020
Credits: 1.50 CME / MOC
Medical Learning Institute, Inc.
Moving in Leaps and Bounds Toward Expanded Precision Treatment of HER2- or HER3-Driven Breast, Gastrointestinal, Lung, and Other Cancers: Current Challenges, Opportunities for Improvement, and Practical Considerations
Erika Hamilton, MD
August 6, 2020
Credits: 1.00 CNE
Medical Learning Institute, Inc.
Rethinking Patient Care in Endometrial and Cervical Cancer: How Nurses Can Lead the Targeted and Immunotherapeutic Revolution
Kimberly Halla, MSN, FNP-C
August 5, 2020
Credits: 1.00 CME
Medical Learning Institute, Inc.
Current and Emerging Therapies for Endometriosis and Uterine Fibroids: What Do You Need to Know?
Georgine Lamvu, MD, MPH
August 3, 2020
Credits: 1.00 CME / MOC
Medical Learning Institute, Inc.
Evidence Informing Practice: Changing Standards of Care for Use of CDK4 and 6 Inhibitors in the Treatment of Breast Cancer
Joyce O’Shaughnessy, MD
July 23, 2020
Credits: 1.00 CME / MOC
Medical Learning Institute, Inc.
Harnessing the Immune System in the Treatment of Triple-Negative Breast Cancer to Maximize Benefits to Patients: State of the Science, Key Trials, Implications for Practice, and Patient-Centric Clinical Decision-Making
Heather L. McArthur, MD, MPH
July 22, 2020
Credits: 1.00 CME / MOC
Medical Learning Institute, Inc.
Optimizing Precision Medicine in Ovarian Cancer: Expert Insights on Clinical Implications of PARP Inhibitor Therapy and Companion Diagnostics
Bradley J. Monk, MD, FACS, FACOG
July 21, 2020
Credits: 1.00 CME / MOC
Medical Learning Institute, Inc.
Practical Perspectives on Rapid Change in Endometrial and Cervical Cancer Management: Exploring Innovative Therapy in Gynecologic Malignancies
Linda R. Duska, MD, MPH
July 17, 2020
Credits: 0.50 CME / MOC
Medical Learning Institute, Inc.
Chair's Take on Harnessing the Immune System in the Treatment of TNBC and Beyond: Where Are We Now and Where Are We Going Next?
Heather L. McArthur, MD, MPH
July 9, 2020
Credits: 0.50 CME / MOC
Medical Learning Institute, Inc.
Chair's Take: Latest and Emerging Evidence of PARP Inhibitors in Ovarian Cancer Management
Bradley J. Monk, MD, FACS, FACOG
June 18, 2020
Credits: 0.50 CME / MOC
Medical Learning Institute, Inc.
Chair’s Take on Advances in Gynecologic Cancer Care: Exploring New Advances and Innovative Therapies in Endometrial and Cervical Cancers
Linda R. Duska, MD, MPH
June 16, 2020
Credits: 0.50 CME / MOC
Medical Learning Institute, Inc.
Expert Views on the Evolving Role of PARP Inhibitors in the Treatment of Ovarian Cancer
Bradley J. Monk, MD, FACS, FACOG
April 30, 2020
Medical Learning Institute, Inc.
On the Cusp of the Era of Immuno-Oncology in Triple-Negative Breast Cancer: Rational Strategies to Make the Most of Immunotherapies and Other Effective Treatment Modalities Throughout the Disease Continuum
Peter Schmid, FRCP, MD, PhD
December 30, 2019
Penn State College of Medicine
Advances in Precision Care in Solid Tumor Oncology: Defining the Role of PARP Inhibitors
Robert Coleman, MD
November 8, 2019